Literature DB >> 30477938

Metastatic osteosarcoma challenged by regorafenib.

Dominique Heymann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30477938     DOI： 10.1016/S1470-2045(18)30821-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  LncRNA THOR increases osteosarcoma cell stemness and migration by enhancing SOX9 mRNA stability.

Authors:  Haojun Wu; Yanxia He; Hang Chen; Yanzhi Liu; Bo Wei; Guanghua Chen; Han Lin; Hao Lin
Journal:  FEBS Open Bio       Date:  2019-03-20       Impact factor: 2.693

Review 2.  Osteoimmunology of Oral and Maxillofacial Diseases: Translational Applications Based on Biological Mechanisms.

Authors:  Carla Alvarez; Gustavo Monasterio; Franco Cavalla; Luis A Córdova; Marcela Hernández; Dominique Heymann; Gustavo P Garlet; Timo Sorsa; Pirjo Pärnänen; Hsi-Ming Lee; Lorne M Golub; Rolando Vernal; Alpdogan Kantarci
Journal:  Front Immunol       Date:  2019-07-18       Impact factor: 8.786

3.  Sevoflurane Inhibited Osteosarcoma Cell Proliferation And Invasion Via Targeting miR-203/WNT2B/Wnt/β-Catenin Axis.

Authors:  Meixian Chen; Lisheng Zhou; Zhaoxia Liao; Xijiu Ye; Xujun Xuan; Beibei Gu; Fuding Lu
Journal:  Cancer Manag Res       Date:  2019-11-11       Impact factor: 3.989

Review 4.  Precision Medicine in Osteosarcoma: MATCH Trial and Beyond.

Authors:  Elisa Tirtei; Anna Campello; Sebastian D Asaftei; Katia Mareschi; Matteo Cereda; Franca Fagioli
Journal:  Cells       Date:  2021-01-31       Impact factor: 6.600

5.  A simple, universal and multifunctional template agent for personalized treatment of bone tumors.

Authors:  Wei-Bo Liu; Su-He Dong; Wen-Hao Hu; Meng Gao; Teng Li; Quan-Bo Ji; Xiao-Qing Yang; Deng-Bin Qi; Zhen Zhang; Ze-Long Song; Yu-Jie Liu; Xue-Song Zhang
Journal:  Bioact Mater       Date:  2021-10-26

6.  ATG16L1 is a Potential Prognostic Biomarker and Immune Signature for Osteosarcoma: A Study Based on Bulk RNA and Single-Cell RNA-Sequencing.

Authors:  Zhaojie Qin; Kai Luo; Wenyu Feng; Xinli Zhan; Yun Liu; Shijie Liao; Juliang He; Mingwei He; Tianyu Xie; Xiaohong Jiang; Boxiang Li; Huijiang Liu; Qian Huang; Haijun Tang
Journal:  Int J Gen Med       Date:  2022-02-02

7.  The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress.

Authors:  Jinqiong Jiang; Weida Wang; Weineng Xiang; Lin Jiang; Qian Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Silencing of the Long Non-Coding RNA TTN-AS1 Attenuates the Malignant Progression of Osteosarcoma Cells by Regulating the miR-16-1-3p/TFAP4 Axis.

Authors:  Xianghai Meng; Zhenjun Zhang; Lin Chen; Xi Wang; Qingguo Zhang; Shuheng Liu
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.